GET DAILY SIGNALSPasithea Therapeutics Corp. (KTTA): Clinical Progress on PAS-004 and the 2026 NF1 Readout
Key Takeaways
- Upcoming data catalyst: The company plans to present NF1-PN (plexiform neurofibroma) Phase 1/1b data in the second half of 2026, including efficacy readouts through the six-month timepoint.
- Differentiated drug profile: PAS-004 is positioned as a potentially best-in-class MEK inhibitor, with interim data showing a favorable safety profile suited to long-term, once-daily chronic dosing.
- Extended financial runway: A $60 million public offering completed in late 2025 is expected to fund operations through at least the first half of 2028.
- Thin but constructive analyst coverage: Consensus stands at a Moderate Buy, with a single covering firm (HC Wainwright) maintaining a Buy rating and a $3.00 price target.
- Structural risk: As a pre-revenue company with no approved products, KTTA remains highly sensitive to clinical outcomes, regulatory decisions, and future dilution.
Pasithea’s Position in Precision Oncology and Rare Disease
Pasithea Therapeutics Corp. (KTTA) focuses on treatments for rare neurological conditions and certain cancers. Its lead candidate, PAS-004, is an oral macrocyclic MEK 1/2 inhibitor aimed at neurofibromatosis type 1 and oncology indications. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Interim Phase 1 data from mid-2026 showed no dose-limiting toxicities or treatment-related discontinuations across 34 patients, with mostly mild adverse events and notably low rates of rash or gastrointestinal issues.
The long half-life of about 60 hours supports once-daily dosing, which could matter for chronic use in NF1-PN where patients often need years of therapy. That said, KTTA is still a small operation with roughly five employees and no marketed products, so execution on clinical milestones will determine how it stacks up against larger competitors.
Catalysts to Watch in the Near Term
The main near-term event is the NF1-PN Phase 1/1b data expected in the second half of 2026, covering efficacy through six months for both plexiform and cutaneous neurofibromas along with updated safety and pharmacokinetic details. This readout could influence sentiment meaningfully given the program’s lead status. Additional steps include ongoing dose escalation in the cancer trial up to 52 mg and a new food-effect study. HC Wainwright reiterated its Buy rating and $3.00 target in April 2026, though coverage from only one firm leaves room for volatility in views.
Industry Context and Financing Considerations
Clinical-stage biotechs like KTTA are more sensitive to capital markets and regulatory trends than to everyday economic cycles. The late-2025 financing extended the runway into the first half of 2028, which helps ease near-term pressure. Broader interest in rare-disease and precision-oncology assets continues because of orphan-drug incentives and unmet need, though policy developments around drug pricing could play a longer-term role.
2026 Outlook and Longer-Term Considerations
The key question heading into 2026 is whether the safety signals seen so far can translate into strong efficacy data that supports later-stage development or potential partnerships. A positive NF1-PN readout would be important; weaker results might shift focus to earlier programs such as PAS-003 in ALS or PAS-001 in schizophrenia. Capital allocation once the current cash is used, along with the company’s ability to control costs as trials grow, will also matter. The $3.00 consensus target reflects one analyst’s view and underscores the wide range of possible outcomes in early-stage biotech.
AI Tools in My Research Process
I often turn to Tickeron’s AI Trend Prediction Engine when evaluating names with upcoming clinical events. The tool offers AI-powered directional forecasts that help assess potential short-term trends and provide historical context alongside the fundamental work on catalysts and runway. It serves as a useful complement when monitoring binary biotech setups like the one ahead for KTTA.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
KTTA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for KTTA turned positive on November 03, 2026. Looking at past instances where KTTA's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on KTTA as a result. In 70 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
KTTA moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where KTTA advanced for three days, in 141 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KTTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KTTA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KTTA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. KTTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.388) is normal, around the industry mean (3.498). P/E Ratio (-0.429) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KTTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement